throbber
(12) United States Patent
`US 6,995,186 B2
`(10) Patent No.:
`Castillo et al.
`
`(45) Date of Patent: Feb. 7, 2006
`
`USOO6995186B2
`
`(54) OLOPATADINE FORMULATIONS FOR
`TOPICAL ADMINISTRATION
`
`(75)
`
`Inventors: Ernesto J. Castillo, Arlington, TX
`(US); Wesley Wehsin Han, Arlington,
`TX (US); Huixiang Zhang, Fort Worth,
`TX (US); Haresh G. Bhagat, Fort
`Worth, TX (US); Onkar N. Singh,
`Arlington, TX (US); Joseph Paul
`Bullock, Fort Worth, TX (US); Suresh
`C. Dixit, Fort Worth, TX (US)
`
`(73) Assignee: Alcon, Inc., Hunenberg (CH)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 511 days.
`
`(21) Appl. No.: 10/175,106
`
`(22)
`
`Filed:
`
`Jun. 19, 2002
`
`(65)
`
`Prior Publication Data
`US 2003/0055102 A1 Mar. 20, 2003
`
`(60)
`
`(51)
`
`Related US. Application Data
`Provisional application No. 60/301,315, filed on Jun. 27,
`2001.
`
`Int. Cl.
`A61K 31/335
`
`(2006.01)
`
`........................................ 514/450; 514/912
`(52) US. Cl.
`(58) Field of Classification Search ................. 514/450,
`514/912
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`6/1988 Wenig ..................... 514/225.2
`4,749,700 A
`10/1989 Lever, Jr. et al.
`........... 549/354
`4,871,865 A
`5/1990 Lever, Jr. et al.
`514/450
`4,923,892 A
`
`............. 514/450
`5/1992 Oshima et al.
`5,116,863 A
`11/1992 Hettche ...................... 424/489
`5,164,194 A
`6/1997 Hayakawa et a1.
`......... 514/450
`5,641,805 A
`6,146,622 A * 11/2000 Castillo et al.
`.......... 424/78.02
`6,174,914 B1
`1/2001 Yanni et al.
`................ 514/450
`6,207,684 B1
`3/2001 Aberg ........................ 514/324
`6,316,483 B1
`11/2001 Haslwanter et a1.
`........ 514/401
`6,333,044 B1
`12/2001 Santus et al.
`............... 424/434
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`W0
`
`0 048 023
`0 214 779
`0 235 796
`WO 91/54687 A1
`
`3/1982
`3/1987
`9/1987
`8/2001
`
`OTHER PUBLICATIONS
`
`Church, “Is Inhibition of Mast Cell Mediator Release Rel-
`evant
`to the Clinical Activity of Anti—allergic Drugs?,”
`Agents and Actions, vol. 18, 3A, pp. 288—293 (1986).
`
`Clegg et al., “Histamine Secretion from Human Skin Slices
`Induced by Anti—IgE and Artificial Secretagogues and the
`Effects of Sodium Cromoglycate and Salbutanol,” Clin.
`Allergy, vol. 15, pp. 321—328 (1985).
`Hamilton et al., “Comarison of a New Antihistaminic and
`Antiallergic Compound KW 46790 With Terfenadine and
`Placebo on Skin and Nasal Provocation in Atopic Individu-
`als,” Clinical and Experimental Allergy, vol. 24, pp.
`955—959 91994).
`Ikeda et al., “Effects of Oxatomide and KW—4679 on
`Acetylcholine—Induced Responses in the Isolated Acini of
`Guinea Pig Nasal Glands,” Int. Arch. Immunol, vol. 106, p.
`157—162 (1995).
`
`Irani etal., “Mast Cell Heterogeneity,” Clinical and Experi-
`mental Allergy, vol. 19, pp. 143—155 (1989).
`
`Kamei et al., “Effects of Certain Antiallergic Drugs on
`Experimental Conjuctivitis in Guinea Pigs,” Atarashii
`Ganka, vol. 11(4), p. 603—605 (1994) (abstract only).
`
`Kamei et al., “Effect of (Z)—11—[3—(Dimethylamino) propy-
`lidene]—6,
`11—dihydrodibenz[b,e]oxepin—2—acetic Acid
`Hydrochloride on Experimental Allergic Conjuctivitis and
`Rhinitis in Rats and Guinea Pigs,” Arzneimittelforschang,
`vol. 45(9), p. 1005—1008 (1995).
`
`Ohshima et al., “Synthesis and Antiallergic Activity of
`11—(Aminoa1kylidene)—6,11,dihydrodibenz[b,e]oxepin
`Derivatives,” J. Medicinal Chemistry, vol. 35(11), p.
`2074—2084 (1992).
`
`Pearce et al., “Effect of Disodium Cromoglycate on Antigen
`Evoked Histamine Release in Human Skin,” Clinical Exp.
`Immunol, vol. 17, pp. 437—440 (1974).
`
`Sharif et al., “Characterization of the Ocular Antiallergic and
`Antihistaminic Effects of Olopatadine (AL—4943A), a Novel
`Drug for Treating Ocular Allergic Diseases,” J. ofPharma-
`c0l0gy and Experimental Therapeaticsl, vol. 278(3), p.
`1252—1261 (1996).
`
`Sharif et al., “Olopatadine (AL—4943A): Pharmacological
`Profile of a Novel Anti—histaminic/Anti—allergic Drug for
`Use in Allergic Conjunctivitis,” Investigative Ophthalmol-
`ogy & Visual Sciencevol. 37(3), p. 1027 (1996) (abstract
`only).
`
`Siraganian, “An Automated Continuous Flow System for the
`Extraction and Fluorometric Analysis of Histamine,” Anal.
`Biochem., vol. 57, pp. 383—394 (1974).
`
`(Continued)
`
`Primary Examiner—Zohreh Fay
`(74) Attorney, Agent, or Firm—Patrick M. Ryan
`
`(57)
`
`ABSTRACT
`
`Topical formulations of Olopatadine for treatment of allergic
`or inflammatory disorders of the eye and nose are disclosed.
`The aqueous formulations contain approximately
`0.17—0.62% (W/v) of Olopatadine and an amount of polyvi-
`nylpyrrolidone or polystyrene sulfonic acid sufficient
`to
`enhance the physical stability of the formulations.
`
`16 Claims, No Drawings
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1005, Page 1
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 1
`
`

`

`US 6,995,186 132
`Page 2
`
`OTHER PUBLICATIONS
`
`Spitalny et al., “Olopatadine Ophthalmic Solution Decreases
`Itching and Redness Associated With Allergic Conjunctivi-
`tis,” Investigative Ophthalmology & Visual Science, vol.
`37(3), p. 593 (1996) (abstract only).
`“The Lung,” Scientific Foundation, Raven Press, Ltd., New
`York, Ch. 3.4.11 (1991).
`Yanni et al., “The In Vitro and In Vivo Ocular Pharmacology
`of Olopatadine (AL—4943A), An Effective Anti—allergic/
`
`Anti—histaminic Agent,” Investigative Ophthalmology &
`Visual Science, vol. 37(3), p. 1028 (1996) (abstract only).
`Zhang et al., “Optically Active Analogues of Ebastine:
`Synthesis and Effect of Chirality on Their Antihistaminic
`and Antimuscarinic Activity,” Chirality, vol. 6(8), p.
`631—641 (1994).
`Astelin® Nasal Spray Product Insert.
`
`* cited by examiner
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1005, Page 2
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 2
`
`

`

`US 6,995,186 B2
`
`1
`OLOPATADINE FORMULATIONS FOR
`TOPICAL ADMINISTRATION
`
`This application claims priority to US. Provisional
`Application Ser. No. 60/301,315, filed Jun. 27, 2001.
`
`BACKGROUND OF THE INVENTION
`
`1. Field of the Invention
`
`The present invention relates to topical formulations used
`for
`treating allergic and inflammatory diseases. More
`particularly, the present invention relates to formulations of
`olopatadine and their use for treating and/or preventing
`allergic or inflammatory disorders of the eye and nose.
`2. Description of the Related Art
`As taught in US. Pat. Nos. 4,871,865 and 4,923,892, both
`assigned to Burroughs Wellcome Co.
`(“the Burroughs
`Wellcome Patents”), certain carboxylic acid derivatives of
`doxepin, including olopatadine (chemical name: Z-11-(3-
`dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]
`oxepine-2-acetic acid), have antihistamine and antiasthmatic
`activity. These two patents classify the carboxylic acid
`derivatives of doxepin as mast cell stabilizers with antihis-
`taminic action because they are believed to inhibit
`the
`release of autacoids (i.e., histamine, serotonin, and the like)
`from mast cells and to inhibit directly histamine’s effects on
`target tissues. The Burroughs Wellcome Patents teach vari-
`ous pharmaceutical formulations containing the carboxylic
`acid derivatives of doxepin, including nasal spray and oph-
`thalmic formulations. See, for example, Col. 7, lines 7—26,
`and Examples 8 (H) and 8 (I) of the ”865 patent.
`US. Pat. No. 5,116,863, assigned to Kyowa Hakko
`Kogyo Co., Ltd., (“the Kyowa patent”), teaches that acetic
`acid derivatives of doxepin and, in particular, olopatadine,
`have anti-allergic and anti-inflammatory activity. Olopata-
`dine is the cis form of the compound having the formula:
`
`CHZCH2N(CH3)2
`
`CHZCOOH
`
`O
`
`Medicament forms taught by the Kyowa patent for the acetic
`acid derivatives of doxepin include a wide range of accept-
`able carriers; however, only oral and injection administra-
`tion forms are mentioned.
`
`US. Pat. No. 5,641,805, assigned to Alcon Laboratories,
`Inc. and Kyowa Hakko Kogyo Co., Ltd., teaches topical
`ophthalmic formulations containing olopatadine for treating
`allergic eye diseases. According to the ’805 patent,
`the
`topical formulations may be solutions, suspensions or gels.
`The formulations contain olopatadine, an isotonic agent, and
`“if required, a preservative, a buffering agent, a stabilizer, a
`viscous vehicle and the like.”See Col. 6,
`lines 30—43.
`“[P]olyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid
`or the like” are mentioned as the viscous vehicle. See Col.
`6, lines 55—57.
`PATANOL® (olopatadine hydrochloride ophthalmic
`solution) 0.1% is currently the only commercially available
`olopatadine product for ophthalmic use. According to its
`labelling information, it contains olopatadine hydrochloride
`equivalent
`to 0.1% olopatadine, 0.01% benzalkonium
`chloride, and unspecified amounts of sodium chloride, diba-
`
`2
`sic sodium phosphate, hydrochloric acid and/or sodium
`hydroxide (to adjust pH) and purified water. It does not
`contain polyvinyl alcohol, polyvinylpyrrolidone, poly-
`acrylic acid or any other polymeric ingredient.
`Topical olopatadine formulations that have prolonged
`therapeutic activity and are effective as products for treating
`allergic or inflammatory conditions in the eye and nose are
`desirable. Topical olopatadine formulations that are effective
`as once-a-day products for treating allergic conditions in the
`eye are desirable.
`
`SUMMARY OF THE INVENTION
`
`The present invention provides topical olopatadine for-
`mulations that are effective as once-a-day products for
`treating allergic or inflammatory disorders of the eye and are
`effective for treating allergic or inflammatory disorders of
`the nose. The formulations of the present
`invention are
`aqueous solutions that comprise approximately 02—06%
`olopatadine. In addition to their relatively high concentra-
`tion of olopatadine, they also contain an amount of polyvi-
`nylpyrrolidone or polystyrene sulfonic acid sufficient
`to
`enhance the physical stability of the solutions.
`Among other factors, the present invention is based on the
`finding that polyvinylpryrrolidone and polystyrene sulfonic
`acid, unlike polyvinyl alcohol and the polyacrylic acid
`carbomer 974P, enhance the physical stability of solutions
`containing approximately 02—06% olopatadine.
`DETAILED DESCRIPTION OF THE
`INVENTION
`
`Unless indicated otherwise, all component amounts are
`presented on a % (w/v) basis and all references to olopata-
`dine are to olopatadine free base.
`Olopatadine is a known compound that can be obtained
`by the methods disclosed in US. Pat. No. 5,116,863, the
`entire contents of which are hereby incorporated by refer-
`ence in the present specification. The solution formulations
`of the present invention contain 0.17—0.62% olopatadine.
`Preferably, the solution formulations intended for use in the
`eye contain 0.17—0.25% olopatadine, and most preferably
`0.18—0.22% olopatadine. Preferably, the solution formula-
`tions intended for use in the nose contain 0.38—0.62%
`olopatadine.
`Generally, olopatadine will be added in the form of a
`pharmaceutically acceptable salt. Examples of the pharma-
`ceutically acceptable salts of olopatadine include inorganic
`acid salts such as hydrochloride, hydrobromide, sulfate and
`phosphate; organic acid salts such as acetate, maleate,
`fumarate,
`tartrate and citrate; alkali metal salts such as
`sodium salt and potassium salt; alkaline earth metal salts
`such as magnesium salt and calcium salt; metal salts such as
`aluminum salt and Zinc salt; and organic amine addition salts
`such as triethylamine addition salt
`(also known as
`tromethamine), morpholine addition salt and piperidine
`addition salt. The most preferred form of olopatadine for use
`in the solution compositions of the present invention is the
`hydrochloride salt of (Z)-11-(3-dimethylaminopropylidene)-
`6,11-dihydro-dibenz-[b,e]oxepin-2-acetic acid. When olo-
`patadine is added to the compositions of the present inven-
`tion in this salt form, 0.222% olopatadine hydrochloride is
`equivalent to 0.2% olopatadine free base, 0.443% olopata-
`dine hydrochloride is equivalent to 0.4% olopatadine free
`base, and 0.665% olopatadine hydrochloride is equivalent to
`0.6% olopatadine free base.
`In addition to olopatadine, the aqueous solution compo-
`sitions of the present invention comprise polyvinylpyrroli-
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1005, Page 3
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 3
`
`

`

`US 6,995,186 B2
`
`3
`done or polystyrene sulfonic acid in an amount sufficient to
`enhance the physical stability of the composition. Polyvi-
`nylpyrrolidone and polystyrene sulfonic acid are known
`polymers and both are commercially available from a vari-
`ety of sources in different grades and in a number of
`molecular weights. For example, polyvinylpyrrolidone is
`available in many grades from International Specialty Prod-
`ucts (Wayne, N.J.): Plasdone® C-15 (weight avg. MW=8K),
`K-26/28 (weight avg. MW=30K), K-29/32 (weight avg.
`MW=58K), K-30 (weight avg. MW=50K) and K-90 (weight
`avg. MW=1300K). Also, polyvinylpyrrolidone is available
`from BASF Corporation under the Kollidon brand name. As
`used herein, “polyvinylpyrrolidone” includes homopoly-
`mers of vinylpyrrolidone and copolymers of vinylpyrroli-
`done and vinyl acetate. Vinylpyrrolidone-vinyl acetate
`copolymers are known as “copovidone” and are commer-
`cially available from BASF Corporation as Kollidon VA 64.
`The polyvinylpyrrolidone ingredient included in the solution
`compositions of the present invention has a weight average
`molecular weight of 5000—1,600,000. Most preferred is
`polyvinylpyrrolidone having a weight average molecular
`weight of 50,000—60,000. In general, the amount of poly-
`vinylpyrrolidone contained in the compositions of the
`present invention will be 0.1—3%, preferably 0.2—2%, and
`most preferably 1.5—2%.
`Polystyrene sulfonic acid is commercially available in
`many grades, including for example the following grades
`available from Alco Chemical, a division of National Starch
`& Chemical Company: Versa TL-70 (weight avg. MW=75,
`000), Versa TL-125 (weight avg. MW=200,000), and Versa
`TL-502 (weight avg. MW=1,000,000). As used herein,
`“polystyrene sulfonic acid” includes homopolymers of sty-
`rene sulfonic acid and salts, as well as copolymers of styrene
`sulfonic acid and maleic anhydride. The polystyrene sul-
`fonic acid ingredient included in the solution compositions
`of the present invention has a weight average molecular
`weight of 10,000—1,500,000, preferably 75,000 to 1,000,
`000, and most preferably 75,000. In general, the amount of
`polystyrene sulfonic acid contained in the compositions of
`the present invention will be 0.1—1%, preferably 0.15—0.4%,
`and most preferably 0.25%.
`invention comprise
`The compositions of the present
`0.17—0.62% olopatadine and a polymeric physical stability-
`enhancing ingredient consisting essentially of polyvinylpyr-
`rolidone or polystyrene sulfonic acid in an amount sufficient
`to enhance the physical stability of the solution. The com-
`positions of the present invention do not contain polyvinyl
`alcohol, polyvinyl acrylic acid, hydroxypropylmethyl
`cellulose, sodium carboxymethyl cellulose, xanthan gum or
`other polymeric physical stability enhancing ingredient.
`The compositions of the present invention have a viscos-
`ity of 0.5—10 cps, preferably 0.5—5 cps, and most preferably
`1—2 cps. This relatively low viscosity insures that
`the
`product is comfortable, does not cause blurring, and is easily
`processed during manufacturing, transfer and filling opera-
`tions.
`
`In addition to the olopatadine and polyvinylpyrrolidone
`ingredients,
`the compositions of the present
`invention
`optionally comprise one or more excipients. Excipients
`commonly used in pharmaceutical compositions intended
`for topical application to the eyes or nose, such as solutions
`or sprays, include, but are not limited to, tonicity agents,
`preservatives, chelating agents, buffering agents, surfactants
`and antioxidants. Suitable tonicity-adjusting agents include
`mannitol, sodium chloride, glycerin, sorbitol and the like.
`Suitable preservatives include p-hydroxybenzoic acid ester,
`benzalkonium chloride, benzododecinium bromide,
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`polyquaternium-1 and the like. Suitable chelating agents
`include sodium edetate and the like. Suitable buffering
`agents include phosphates, borates, citrates, acetates and the
`like. Suitable surfactants include ionic and nonionic
`surfactants, though nonionic surfactants are preferred, such
`as polysorbates, polyethoxylated castor oil derivatives and
`oxyethylated tertiary octylphenol formaldehyde polymer
`(tyloxapol). Suitable antioxidants include sulfites,
`ascorbates, BHA and BHT. The compositions of the present
`invention optionally comprise an additional active agent.
`With the exception of the optional preservative ingredient
`(e.g., polyquaternium-1),
`the compositions of the present
`invention preferably do not contain any polymeric ingredi-
`ent other than polyvinylpyrrolidone or polystyrene sulfonic
`acid.
`
`Particularly for compositions intended to be administered
`as eye drops, the compositions preferably contain a tonicity-
`adjusting agent in an amount sufficient to cause the final
`composition to have an ophthalmically acceptable osmola-
`lity (generally 150—450 mOsm, preferably 250—350 mOsm).
`The ophthalmic compositions of the present invention pref-
`erably have a pH of 4—8, preferably a pH of 6.5—7.5, and
`most preferably a pH of 6.8—7.2. Compositions of the
`present invention intended for use in the nose preferably
`have a pH of 3.5—8. Preferably, compositions intended to be
`administered to the nose have a pH of 3.5—4.5, and most
`preferably a pH of 3.8—4.4.
`When the compositions of the present invention contain
`polyvinylpyrrolidone, the polyvinylpyrrolidone ingredient is
`preferably selected or processed to minimize peroxide con-
`tent. Freshly produced batches of polyvinylpyrrolidone are
`preferred over aged batches. Additionally, particularly in
`cases where the composition will contain greater than 0.5%
`polyvinylpyrrolidone,
`the polyvinylpyrrolidone ingredient
`should be thermally treated (i.e., heated to a temperature
`above room temperature) prior to mixing with olopatadine in
`order to reduce the amount of peroxides in the polyvinylpyr-
`rolidone ingredient and minimize the effect of peroxides on
`the chemical stability of olopatadine. While thermally treat-
`ing an aqueous solution of polyvinylpyrrolidone for pro-
`longed periods will substantially reduce the amount of
`peroxides, it can lead to discoloration (yellow to yellowish-
`brown) of the polyvinylpyrrolidone solution. In order to
`substantially reduce or eliminate peroxides without discol-
`oring the polyvinylpyrrolidone solution, the pH of the aque-
`ous solution of polyvinylpyrrolidone should be adjusted to
`pH 11—13 before it is subjected to heat. Much shorter heating
`times are needed to achieve significant reductions in perox-
`ide levels if the pH of the polyvinylpyrrolidone solution is
`elevated.
`
`One suitable method of thermally treating the polyvi-
`nylpyrrolidone ingredient is as follows. First, dissolve the
`polyvinylpyrrolidone ingredient in purified water to make a
`4—6% solution,
`then raise the pH of the solution to pH
`11—13, preferably 11—11.5, then heat to a temperature in the
`range of 60—121° C., preferably 65—80° C. and most pref-
`erably 70—75° C. The elevated temperature should be main-
`tained for approximately 30—120 minutes (preferably 30
`minutes). After
`the heated solution cools to room
`temperature, add HCl to adjust the pH to 3.5—8, depending
`upon the target pH for the olopatadine composition.
`The compositions of the present invention are preferably
`packaged in opaque plastic containers. Apreferred container
`for an ophthalmic product is a low-density polyethylene
`container that has been sterilized using ethylene oxide
`instead of gamma-irradiation. A preferred container for a
`nasal product
`is a high-density polyethylene container
`equipped with a nasal spray pump.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1005, Page 4
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 4
`
`

`

`US 6,995,186 B2
`
`5
`Certain embodiments of the invention are illustrated in the
`
`following examples.
`
`EXAMPLE 1
`-
`-
`-
`-
`-
`Topically Administrable Ophthalmic Solution
`
`Ingredient
`
`(Z)—11-(3-dimethylaminopropylidene)-
`6,11-dihydrodibenz[b,e]oxepin-2—acetic
`acid.HCl
`
`(“OloPatadme'HCI”)
`Polyvmylpyrrolidone
`Sodium Chloride
`Benzalkonium Chloride
`Edetate Disodium
`Dibasic Sodium Phosphate (Anhydrous)
`NaOH/HCl
`Purified Water
`
`*equivalent to 0.2% free base
`
`Concentration (% w/v)
`
`0.222"
`
`1.6—2.0
`0.55
`0—0.02
`0.01
`0.5
`q.s. pH 7.0 1 0.2
`q.s. 100
`
`5
`
`15
`
`20
`
`25
`
`6
`then
`the pH to approximately pH 6.5,
`to adjust
`N—lauroylsarcosine and then the drug is added, followed by
`final pH adjustment to pH 6.5 and addition of the remaining
`amount of purified water, with mixing after adding each
`in redient The resultin solution is then filtered throu h a
`g. .
`.
`‘
`g
`.
`.
`.
`g
`sterilizing filter and transferred under sterile conditions into
`ethylene oxide-sterilized LDPE or polypropylene contain-
`ers.
`
`EXAMPLE 3
`
`Topically Administrable Nasal Solution
`
`Ingredient
`
`Concentration (% w/v)
`
`Olopatadine.HCl
`Polyvinylpyrrolidone
`Sodium Chloride
`Benzalkonium Chloride
`Edetate Disodium
`Dibasic Sodium Phosphate (Anhydrous)
`NaQH/HCI
`Punfied water
`*equivalent to 02% free base
`
`0.222"
`1.6—2.0
`0.3—0.6
`0—0.02
`0.01
`0.5
`Q-S- PH 3-8-7
`q's' 100
`
`.
`.
`.
`A representative compounding procedure for the solution
`composition of this Example is provided below.
`Preparation of Polyvinylpyrrolidone Stock Solution
`A 4% stock solution of polyvinylpyrrolidone is prepared by
`dissolving the polyvinylpyrrolidone in purified water, add-
`ing NaOH to raise the pH to 11.5, and heating for 30 minutes
`at 70—750 0 After (3091ng to room temperature, HCl is
`added to the stock solution to adjust the pH to 7.
`Compounding Procedure
`Preparation of Polyvinylpyrrolidone Stock Solution
`Purified water, dibasic sodium phosphate, sodium chloride,
`A4% stock solution of polyvinylpyrrolidone is prepared by
`edetate dISOdlum’ benzalkonium chloride (as 1% SFOCk
`.
`.
`.
`.
`.
`.
`solution) and polyVinylpyrrolidone (as 4% stock solution)
`dissolVing the polyVinylpyrrolidone in purified water, add-
`.
`.
`.
`.
`.
`.
`.
`.
`.
`are added to a container, w1th mix1ng after adding each 35
`ing NaOH to raise the pH to 11.5, and heating for 30 minutes
`.
`.
`.
`.
`.
`o
`.
`.
`ingredient. NaOH is added to adjust the pH to approx1mately
`at 70—75 C. After cooling to room temperature, HCl is
`.
`.
`dd d
`h
`k
`1
`.
`d'
`h H
`7
`pH 7, then the drug is added, followed by final pH adjust-
`e
`to t e StOC SO ution to a JuSt t e p
`a
`ment to pH 7.0 and the addition of the remaining amount of
`Compounding Procedure
`purified water, with mixing after adding each ingredient. The
`resulting solution IS then filtered through a sterilizmg filter 40 Purified water, dibasic sodium phosphate, sodium chloride,
`and transferred under sterile conditions into ethylene ox1de-
`.
`.
`.
`.
`.
`.
`.
`edetate disodium, benzalkonium chloride (as 1% stock
`sterilized LDPE or polypropylene containers.
`.
`.
`.
`.
`solution), polyVinylpyrrolidone (as 4% stock solution), and
`the drug are. added to a container, with mixing after adding
`45 each ingredient. NaOH/HCl is added to adjust the pH to
`approximately pH 4, and the remaining amount of purified
`water is added. The resulting solution is then filtered through
`a sterilizing filter and aseptically transferred into high-
`densit
`ol eth lene, s ra - um containers.
`y p y
`y
`p y p
`p
`
`Arepresentative compounding procedure for the solution
`30 composition of this Example is provided below.
`
`to
`
`’
`
`EXAMPLE 2
`
`Topically Administrable Ophthalmic Solution
`
`Ingredient
`
`Concentration (% w/v)
`
`50
`
`Olopatadine.HCl
`N-lauroylsarcosine
`Polystyrene Sulfonic Acid
`Mannitol
`Benzalkonium Chloride
`Boric Acid
`Edetate Disodium
`Tromethamine
`Purified Water
`
`*equivalent to 0.2% free base
`
`0.222"
`0.04
`0.5
`4.4
`0—0.02
`0.45
`0.05
`q.s. pH 6.5 1 0.2
`q-S- 100
`
`.
`.
`.
`A representative compounding procedure for the solution
`composition of this Example is provided below.
`Compounding Procedure
`Purified water, mannitol, boric acid, edetate disodium, ben-
`zalkonium chloride (as 1% stock solution) and polystyrene 65
`sulfonic acid (as a powder) are added to a container, with
`mixing after adding each ingredient. Tromethamine is added
`
`60
`
`EXAMPLE 4
`
`.
`.
`.
`.
`Topically Administrable Nasal Solution
`
`55
`
`Ingredient
`
`Concentration (% w/v)
`
`Olopatadine.HCl
`Polyvinylpyrrolidone
`Sodium Chloride
`Benzalkonium Chloride
`Edetate Disodium
`Dibasic Sodium Phosphate (Anhydrous)
`11:11:12;{Rim
`*equivalent to 0.4% free base
`
`0.443"
`1.6—2.0
`0.3—0.6
`0.01 + 3% XS
`0.01
`0.5
`2': $103844
`I
`'
`
`|PR2018—01020 and |PR2018—01021, Exhibit 1005. Page 5
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 5
`
`

`

`US 6,995,186 B2
`
`7
`The solution composition of this Example may be pre-
`pared using the procedure described above for the solution
`composition of Example 3.
`
`EXAMPLE 5
`
`The compositions shown in Table 1 below were prepared
`and subjected to stability studies. In no case was the poly-
`
`8
`meric ingredient autoclaved and none of the compositions
`was filtered through a 0.2 pm filter. One set of samples (two
`vials each) of each of the compositions was subjected to
`three refrigeration-room temperature cycles and a second set
`(two vials each) was subjected to continuous low-
`temperature eXposure. The results are shown in Table 2
`below.
`
`5
`
`TABLE 1
`
`FORMULATION
`
`A
`
`B
`
`C
`
`D
`
`E
`
`F
`
`G
`
`INGREDIENT
`Concentration (% w/w)
`
`
`Olopatadine.HCl
`Polyvinyl Alcohol
`(Airvol 2055)
`HydrOXypropyl
`Methylcellulose (2910)
`Xanthan Gum (AR)
`Carbopol 974P
`Polyvinyl pyrrolidone
`(wt. Avg. MW = 58K)
`Sodium CarbOXymethyl-
`cellulose (762P)
`Benzalkonium
`Chloride
`Sodium Chloride
`DibaSic Sodium
`
`Phosphate (anhydrous)
`NaOH/HCl
`Purified Water
`Viscosity* (cps)
`
`0.222
`0.1
`
`—
`
`—
`—
`—
`
`0.222
`0.222
`0.222
`0.222
`0.222
`0.222
`
`
`
`
`0.05
`
`—
`—
`—
`
`0.02
`—
`—
`
`—
`0.01
`—
`
`—
`—
`1.0
`
`—
`—
`1.8
`
`
`
`—
`—
`—
`
`0.1
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`0.01 +
`1% XS
`0.6
`0.5
`
`q.S. pH 7
`q.S. 100
`1.02
`
`q.S. pH 7
`q.S. 100
`1.40
`
`q.S. pH 7
`q.S. 100
`1.42
`
`q.S. pH 7
`q.S. 100
`0.97
`
`q.S. pH 7
`q.S. 100
`1.20
`
`q.S. pH 7
`q.S. 100
`1.45
`
`q.S. pH 7
`q.S. 100
`1.16
`
`*Brookfield viscometer (60 RPM, CP-42)
`
`TABLE 2
`
`Refrigeration - RT cycles
`
`Continuous ow-temperature eXposure
`
`Formulation One cycle
`
`Tiree cycleS
`
`Day 7
`
`Day 14
`
`C ear, no
`Jar ic eS
`
`A
`
`B
`
`C
`
`D
`
`E
`
`F
`
`G
`
`
`
`C ear, few
`particles (one
`vial)
`C ear, a
`cryStal (2 mm)
`observed in
`one vial)
`C ear, cryStalS
`
`
`
`C ear, few
`particles
`
`C ear,
`particles and
`cryStalS
`
`C ear, cryStalS
`
`C ear, lotS of
`cryStalS
`C ear, no
`particles
`C ear, no
`particles
`C ear, cryStalS
`
`
`
`
`
`C ear, fiber-
`li§e particles
`
`C ear, cryStalS
`and fiber-like
`particles
`
`C ear, cryStalS
`
`C ear, lotS of
`cryStalS
`C ear, no
`particles
`C ear, no
`particles
`C ear, cryStalS
`
`Day 28
`
`C ear,
`particles
`
`C ear, cryStalS
`
`C ear, cryStalS
`
`C ear, cryStalS
`
`C ear, no
`particles
`C ear, no
`particles
`C ear, cryStalS
`
`
`
`C ear, no
`Jar ic eS
`
`
`
`
`
`
`
`C ear, no
`Jar ic eS
`C ear, lotS of C ear, lotS of
`crySta S
`cryStalS
`C ear, no
`C ear, no
`Jar ic eS
`particles
`C ear, no
`C ear, no
`Jar ic eS
`particles
`C ear, no
`C ear, cryStalS
`Jar ic eS
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1005, Page 6
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 6
`
`

`

`US 6,995,186 B2
`
`9
`EXAMPLE 6
`
`10
`
`TABLE 3-continued
`
`FORMULATION
`
`The compositions shown in Table 3 below were subjected 5
`to freeze-thaw stability studies at two conditions (with and
`without seed; seed=0—1/2 Canyon pumice (from Charles B.
`Chrystal Co., Inc., New York, NY.) at 1 mg in 5 mL of
`formulation) and two temperatures (0° C. or —20° C.). In no 10
`case was the polymeric ingredient autoclaved and none of
`the compositions was filtered through a 0.2 pm filter. Each
`of the compositions (two Vials each) was subjected to siX
`freeze-thaw cycles where one cycle was three days at low
`temperature (i.e., either 0° C. or —20° C.), followed by one 15
`day at uncontrolled room temperature. The compositions
`were Visually inspected and the results recorded. The results
`are shown in Table 4 below.
`
`TABLE 3
`
`FORMULATION
`
`H
`
`I
`
`J
`
`Concentration ( % w/w)
`
`0.222
`0.01 + 3% XS
`
`0.222
`0.01 + 3% XS
`
`0.222
`0.01 + 3% XS
`
`0.01
`1.8
`
`—
`—
`
`0.55
`0.5
`
`0.01
`—
`
`0.6
`—
`
`0.55
`0.5
`
`0.01
`—
`
`—
`1.8
`
`0.55
`0.5
`
`20
`
`25
`
`30
`
`35
`
`Ingredient
`
`Olopatadine.HCl
`Benzalkonium
`Chloride
`
`Edetate Disodium
`HydrOXypropyl
`methyl-cellulose
`Carbopol 974P
`Polyvinyl alcohol
`(Airvol 205S)
`Sodium Chloride
`DibaSic Sodium
`
`Phosphate
`(Anhydrous)
`
`Ingredient
`
`NaOH/HCl
`
`Purified Water
`
`H
`
`I
`Concentration ( % w/w)
`
`J
`
`Adjust pH
`7.0 1 0.2
`QS to 100%
`
`Adjust pH
`7.0 1 0.2
`QS to 100%
`
`Adjust pH
`7.0 1 0.2
`QS to 100%
`
`TABLE 4
`FORMULATION
`OBSERVATION
`
`H
`
`I
`
`J
`
`No precipitation after 6 cycles with or without
`seed at either temperature
`Hazy from 1“ cycle onward with or without
`seed at both temperatures
`No precipitation after 6 cycles with or without
`seed at either temperature
`
`EXAMPLE 7
`
`The compositions shown in Table 5 below were subjected
`to freeze-thaw stability studies at two conditions (with and
`without seed; seed=same as in Example 4 above) and two
`temperatures (0° C. or —20° C.). In no case was the poly-
`meric ingredient autoclaved and none of the compositions
`was filtered through a 0.2 pm filter. Each of the compositions
`(three Vials each) was subjected to up to siX freeze-thaw
`cycles where one cycle was three days at low temperature
`(i.e., either 0° C. or —20° C.), followed by one day at
`uncontrolled room temperature. The compositions were
`Visually inspected and the results recorded. The results are
`shown in Table 6 below.
`
`TABLE 5
`
`FORMULATION
`
`K
`
`L
`
`M
`
`P
`
`Q
`
`R
`
`S
`
`INGREDIENT
`
`0.222
`2
`
`Olopatadine.HCl
`Polyvinyl pyrrolidone
`(wt. Avg. MW = 58K)
`Polyethylene Glycol (400) —
`Polyvinyl pyrrolidone
`—
`(wt. avg. MW = 1300K)
`Benzalkonium Chloride
`
`DibaSic Sodium
`
`Phosphate (Anhydrous)
`Sodium Chloride
`Edetate Disodium
`
`NaOH/HCl
`Purified Water
`
`N
`
`O
`
`Concentration (% w/w)
`
`0.222
`1.8
`
`_
`—
`
`0.01 +
`3% XS
`0.5
`
`0.55
`0.02
`
`0.222
`—
`
`_
`1.8
`
`0.01 +
`3% XS
`0.5
`
`0.55
`0.02
`
`0.222
`—
`
`_
`—
`
`0.01 +
`3% XS
`0.5
`
`0.6
`—
`
`0.333
`2
`
`_
`—
`
`0.01 +
`3% XS
`0.5
`
`0.55
`0.02
`
`0.333
`2
`
`0.333
`—
`
`2
`—
`
`0.01
`
`0.5
`
`0.3
`0.01
`
`_
`2
`
`0.01
`
`0.5
`
`0.3
`0.01
`
`0.222
`2
`
`2
`—
`
`0.01
`
`0.5
`
`0.3
`0.01
`
`0.222
`—
`
`2
`—
`
`0.01 +
`3% XS
`0.5
`
`0.3
`0.01
`
`0.01 +
`3% XS
`0.5
`
`0.55
`0.02
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`q.S. pH 7
`q.S. 100
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1005, Page 7
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1005, Page 7
`
`

`

`US 6,995,186 B2
`
`TABLE 6
`
`Observation No. of vials showing precipitation
`
`Formulation # cycles Seed 0° C.
`K
`6
`0/3
`L
`6
`0/3
`M
`6
`0/3
`N
`6
`0/3
`0
`6
`0/3
`P
`5
`1/3
`
`Q
`
`R
`S
`
`5
`
`6
`5
`
`3/3
`
`0/3
`3/3
`(3 cycles)
`
`Seed —20° C.
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`(6 cycles)
`0/3
`(6 cycles)
`0/3
`3/3
`
`EXAMPLE 8
`
`No Seed 0° C. No Seed —20° C.
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`0/3
`2/3
`2/3
`(6 cycles)
`0/3
`(6 cycles)
`0/3
`2/3
`
`3/3
`
`0/3
`3/3
`(3 cycles)
`
`20
`
`TABLE 8
`
`FORMULATION
`
`OBSERVATION
`
`The formulations shown in Table 7 were prepared and
`subjected to freeze-thaw testing for 5.5 cycles. For one set
`of samples, one cycle was defined as one week at 0° C. 25
`followed by one week at uncontrolled room temperature
`(approx. 21° C.). For another set of samples, one cycle was
`defined as one week at —20° C. followed by one week at
`uncontrolled room temperature (approx. 21° C.). The results
`are shown in Table 8.
`
`TABLE 7
`
`FORMULATION
`
`U
`T
`Concentration (% w/w)
`
`0.222
`0.25
`
`0.01
`0.05
`4_4
`0.45
`0.04
`q.s. pH 6.5
`q.s. 100
`
`0.222
`0.5
`
`0.01
`0.05
`4_4
`0.45
`0.04
`q.s. pH 6.5
`q.s. 100
`
`INGREDIENT
`
`Olopatadin.HCl
`Polystyrene Sulfonic Acid
`(Wt. Avg. MW = 1000K)
`Benzalkonium Chloride
`Edetate Disodium
`Mannitol
`Boric Acid
`N-lauroylsarcosine
`Tromethamine/HCl
`Purified Water
`
`T
`U
`
`NO precipitation at either temperature
`N0 PreCiPitatiOH at either temperature
`
`EXAMPLE 9
`
`Seven compositions were prepared and subjected to
`30 freeze-thaw stability studies. Each of the seven composi-
`tions contained purified water, 0.222% (w/w) Olopatadine
`HCl, 0.01% (w/w) (+3% excess) benzalkonium chloride,
`0.06% (w/w) sodium chloride 0.5% (w/w) dibasic sodium
`phosphate, and NaOH/HCl to adjust pH to 7. The seven
`35 samples were differentiated by their amount or grade
`(molecular weight) of polyvinylpyrrolidone ingredient, as
`shown in Table 9. In no case was the polymeric ingredient
`autoclaved and the compositions were filtered through a 0.2
`pm filter. The seven samples were placed in scintillation
`40 Vials containing stir bars and were subjected to freeze-thaw
`stability studies at
`two conditions and two temperatures
`(3—4° C. or —21° C.). After six cycles of 3 days at low
`temperature and one day at room temperature (with stirring),
`the samples were subjected to 3.5 cycles

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket